US Pharma MarketingThe post Olympus’ shares plunge following FDA warning letter over manufacturing failures appeared first on Medical Device Network.
Olympus’ shares plunge following FDA warning letter over manufacturing failures
The FDA’s Warning Letter follows its completion of inspections at six of Olympus’ international manufacturing sites in late 2025. The FDA’s Warning Letter follows its completion of inspections at six of Olympus’ international manufacturing sites in late 2025. The warning letter from the FDA comes as the latest in a series of regulatory woes for Olympus’ quality systems. Credit: nitpicker/Shutterstock.com Olympus Corporation has been hit with a warning letter from the US Food and Drug Administration (FDA) following inspections at its international manufacturing sites, prompting the Japanese conglomerate’s share price to plummet. Olympus received the warning letter on 7 October,…
The FDA’s Warning Letter follows its completion of inspections at six of Olympus’ international manufacturing sites in late 2025.
Source: Medical Device Network